This week in techniques



Licensing status

Publication and contact information


Three-gene signature predictive of indolent prostate cancer

A three-gene signature could help identify patients who have less aggressive forms of prostate cancer. Gene expression analyses of aging and senescence genes and subsequent analysis of samples from patients who have indolent prostate cancer led to the development of a signature consisting of fibroblast growth factor receptor 1 (FGFR1; CD331), cyclin-dependent kinase inhibitor 1A (p21, Cip1; CDKN1A; CIP1) and peripheral myelin protein 22 (PMP22). In a retrospective analysis of patient biopsy samples, expression of proteins in the signature was higher in patients who did not have disease progression. Next steps include prospective and retrospective trials to evaluate this biomarker panel on biopsy samples from independent cohorts.

SciBX 6(40); doi:10.1038/scibx.2013.1150
Published online Oct. 17, 2013

Patent application filed; available for licensing

Irshad, S. et al. Sci. Transl. Med.; published online Sept. 11, 2013;
Contact: Cory Abate-Shen, Columbia University Medical Center,
New York, N.Y.
Contact: Andrea Califano, same affiliation as above